MedTrace Logo

Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease

NCT07685873 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-07-06

No results posted yet for this study

Summary

To evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients.

Conditions

  • Parkinson Disease
  • Parkinson Disease Dementia
  • Parkinson's Disease and Parkinsonism

Interventions

DIAGNOSTIC_TEST

Diagnostic Test: 18F-FPyCO/SMBT-1

Each subject receive a single intravenous injection of 18F-FPyCO/SMBT-1, and undergo PET/ CT or MRI imaging within the specificed time.

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Tianjin Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-25
Primary Completion
2029-07-01
Completion
2029-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07685873 on ClinicalTrials.gov